• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

先天免疫、炎症与肿瘤进展:双刃剑。

Innate immunity, inflammation and tumour progression: double-edged swords.

机构信息

Humanitas Clinical and Research Center - IRCCS, via Manzoni 56, 20089, Rozzano, (Mi), Italy.

Department of Biomedical Sciences, Humanitas University, Pieve Emanuele Milan, Italy.

出版信息

J Intern Med. 2019 May;285(5):524-532. doi: 10.1111/joim.12886. Epub 2019 Mar 14.

DOI:10.1111/joim.12886
PMID:30873708
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7174018/
Abstract

Components of the cellular and the humoral arm of the immune system are essential elements of the tumour microenvironment (TME). The TME includes tumour-associated macrophages which have served as a paradigm for the cancer-promoting inflammation. Cytokines, IL-1 in particular, and complement have emerged as important players in tumour promotion. On the other hand, myeloid cells, innate lymphoid cells and complement have the potential, if unleashed, to mediate anticancer resistance. Targeting checkpoints restraining innate immunity, macrophages and natural killer (NK) cells in particular holds promise as a therapeutic strategy.

摘要

细胞和体液免疫的组成部分是肿瘤微环境 (TME) 的重要元素。TME 包括肿瘤相关巨噬细胞,它们已成为促进癌症炎症的典范。细胞因子,特别是白细胞介素 1 (IL-1) 和补体,已成为肿瘤促进的重要参与者。另一方面,如果释放,髓样细胞、固有淋巴细胞和补体有可能介导抗癌耐药性。作为一种治疗策略,靶向限制先天免疫的检查点、巨噬细胞和自然杀伤 (NK) 细胞具有广阔的前景。

相似文献

1
Innate immunity, inflammation and tumour progression: double-edged swords.先天免疫、炎症与肿瘤进展:双刃剑。
J Intern Med. 2019 May;285(5):524-532. doi: 10.1111/joim.12886. Epub 2019 Mar 14.
2
The Tumor Microenvironment Innately Modulates Cancer Progression.肿瘤微环境先天调节癌症进展。
Cancer Res. 2019 Sep 15;79(18):4557-4566. doi: 10.1158/0008-5472.CAN-18-3962. Epub 2019 Jul 26.
3
Innate lymphoid cells and cancer: Role in tumor progression and inhibition.固有淋巴细胞与癌症:在肿瘤进展与抑制中的作用。
Eur J Immunol. 2021 Sep;51(9):2188-2205. doi: 10.1002/eji.202049033. Epub 2021 Jul 11.
4
Therapeutic Approaches Targeting the Natural Killer-Myeloid Cell Axis in the Tumor Microenvironment.靶向肿瘤微环境中自然杀伤细胞-髓系细胞轴的治疗方法。
Front Immunol. 2021 Apr 19;12:633685. doi: 10.3389/fimmu.2021.633685. eCollection 2021.
5
Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment.临床免疫学评论系列;关注癌症:肿瘤相关巨噬细胞:炎症性肿瘤微环境中无可争议的明星。
Clin Exp Immunol. 2012 Feb;167(2):195-205. doi: 10.1111/j.1365-2249.2011.04515.x.
6
Cytokines Orchestrating the Natural Killer-Myeloid Cell Crosstalk in the Tumor Microenvironment: Implications for Natural Killer Cell-Based Cancer Immunotherapy.细胞因子在肿瘤微环境中协调自然杀伤细胞与髓系细胞的相互作用:对基于自然杀伤细胞的癌症免疫治疗的意义。
Front Immunol. 2021 Jan 29;11:621225. doi: 10.3389/fimmu.2020.621225. eCollection 2020.
7
Autophagy, the innate immune response and cancer.自噬、先天免疫反应与癌症。
Mol Oncol. 2020 Sep;14(9):1913-1929. doi: 10.1002/1878-0261.12774. Epub 2020 Aug 30.
8
LncRNAs as behind-the-scenes molecules in cancer progression through regulating tumor-associated innate immune system cells.长链非编码RNA作为癌症进展中的幕后分子,通过调节肿瘤相关固有免疫系统细胞发挥作用。
Mol Biol Rep. 2025 May 8;52(1):449. doi: 10.1007/s11033-025-10513-3.
9
The Interplay Between Innate Lymphoid Cells and the Tumor Microenvironment.固有淋巴细胞与肿瘤微环境的相互作用。
Front Immunol. 2019 Dec 13;10:2895. doi: 10.3389/fimmu.2019.02895. eCollection 2019.
10
The Multifaceted Role of Macrophages in Oncolytic Virotherapy.巨噬细胞在溶瘤病毒治疗中的多方面作用。
Viruses. 2021 Aug 9;13(8):1570. doi: 10.3390/v13081570.

引用本文的文献

1
Integrating pan-immune-inflammation value into personalized survival prediction of nasopharyngeal carcinoma: a large-scale long-term retrospective study.将泛免疫炎症值纳入鼻咽癌个性化生存预测:一项大规模长期回顾性研究
BMC Cancer. 2025 Jul 21;25(1):1194. doi: 10.1186/s12885-025-14413-4.
2
Crosstalk between cancer‑associated fibroblasts and inflammation in tumor microenvironment: A novel perspective in cancer therapy (Review).肿瘤微环境中癌症相关成纤维细胞与炎症之间的相互作用:癌症治疗的新视角(综述)
Oncol Rep. 2025 Aug;54(2). doi: 10.3892/or.2025.8926. Epub 2025 Jun 13.
3
PD-1 regulates the anti-tumor immune function of macrophages through JAK2-STAT3 signaling pathway in colorectal cancer tumor microenvironment.在结直肠癌肿瘤微环境中,程序性死亡受体1(PD-1)通过Janus激酶2(JAK2)-信号转导子和转录激活子3(STAT3)信号通路调节巨噬细胞的抗肿瘤免疫功能。
J Transl Med. 2025 May 2;23(1):502. doi: 10.1186/s12967-025-06469-4.
4
Lymphocyte/monocyte to lactate dehydrogenase ratio prior to lymphodepletion impact the outcomes of patients with diffused large B cell lymphoma undergoing CAR-T cell therapy.淋巴细胞清除术前淋巴细胞/单核细胞与乳酸脱氢酶比值影响接受CAR-T细胞治疗的弥漫性大B细胞淋巴瘤患者的预后。
Cancer Immunol Immunother. 2025 Mar 15;74(5):148. doi: 10.1007/s00262-025-03987-4.
5
Interactions between tumor-associated macrophages and regulated cell death: therapeutic implications in immuno-oncology.肿瘤相关巨噬细胞与程序性细胞死亡之间的相互作用:免疫肿瘤学中的治疗意义
Front Oncol. 2024 Nov 7;14:1449696. doi: 10.3389/fonc.2024.1449696. eCollection 2024.
6
Protocol for monitoring phagocytosis of cancer cells by TAM-like macrophages using imaging cytometry.使用成像细胞术监测类TAM巨噬细胞对癌细胞吞噬作用的实验方案。
STAR Protoc. 2024 Dec 20;5(4):103320. doi: 10.1016/j.xpro.2024.103320. Epub 2024 Sep 18.
7
Biomimetic Iron-Based Nanoparticles Remodel Immunosuppressive Tumor Microenvironment for Metabolic Immunotherapy.仿生铁基纳米颗粒重塑免疫抑制性肿瘤微环境用于代谢免疫治疗。
Int J Nanomedicine. 2024 Sep 10;19:9333-9349. doi: 10.2147/IJN.S473463. eCollection 2024.
8
Development of a novel colon adenocarcinoma m6A-related lncRNA pair prognostic model.一种新型的结肠腺癌m6A相关长链非编码RNA对预后模型的开发。
Transl Cancer Res. 2024 Jul 31;13(7):3704-3717. doi: 10.21037/tcr-23-1883. Epub 2024 Jul 15.
9
The research progress on radiation resistance of cervical cancer.宫颈癌放射抗性的研究进展
Front Oncol. 2024 Apr 8;14:1380448. doi: 10.3389/fonc.2024.1380448. eCollection 2024.
10
Integrating transcriptomics and machine learning for immunotherapy assessment in colorectal cancer.整合转录组学与机器学习用于结直肠癌免疫治疗评估
Cell Death Discov. 2024 Apr 2;10(1):162. doi: 10.1038/s41420-024-01934-3.

本文引用的文献

1
Aging, inflammation and cancer.衰老、炎症与癌症。
Semin Immunol. 2018 Dec;40:74-82. doi: 10.1016/j.smim.2018.10.011. Epub 2018 Nov 6.
2
Macrophage Checkpoint Blockade in Cancer - Back to the Future.癌症中的巨噬细胞检查点阻断——回归未来
N Engl J Med. 2018 Nov 1;379(18):1777-1779. doi: 10.1056/NEJMe1811699.
3
CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma.Hu5F9-G4 联合利妥昔单抗阻断 CD47 在非霍奇金淋巴瘤中的作用。
N Engl J Med. 2018 Nov 1;379(18):1711-1721. doi: 10.1056/NEJMoa1807315.
4
Targeting IL-1α in cancer cachexia: a narrative review.针对癌症恶病质中的白细胞介素-1α:一篇叙述性综述。
Curr Opin Support Palliat Care. 2018 Dec;12(4):453-459. doi: 10.1097/SPC.0000000000000398.
5
Fluorouracil and bevacizumab plus anakinra for patients with metastatic colorectal cancer refractory to standard therapies (IRAFU): a single-arm phase 2 study.氟尿嘧啶、贝伐单抗联合阿那白滞素用于标准治疗难治性转移性结直肠癌患者(IRAFU):一项单臂2期研究。
Oncoimmunology. 2018 Aug 1;7(9):e1474319. doi: 10.1080/2162402X.2018.1474319. eCollection 2018.
6
Innate Lymphoid Cells: 10 Years On.先天淋巴细胞:十年进展。
Cell. 2018 Aug 23;174(5):1054-1066. doi: 10.1016/j.cell.2018.07.017.
7
The yin-yang of the interaction between myelomonocytic cells and NK cells.髓系细胞与自然杀伤细胞相互作用的阴阳两面。
Scand J Immunol. 2018 Sep;88(3):e12705. doi: 10.1111/sji.12705. Epub 2018 Aug 19.
8
IL1 Receptor Antagonist Controls Transcriptional Signature of Inflammation in Patients with Metastatic Breast Cancer.白细胞介素 1 受体拮抗剂控制转移性乳腺癌患者炎症的转录特征。
Cancer Res. 2018 Sep 15;78(18):5243-5258. doi: 10.1158/0008-5472.CAN-18-0413. Epub 2018 Jul 16.
9
Adaptive NK Cells Resist Regulatory T-cell Suppression Driven by IL37.适应性自然杀伤细胞抵抗由 IL37 驱动的调节性 T 细胞抑制。
Cancer Immunol Res. 2018 Jul;6(7):766-775. doi: 10.1158/2326-6066.CIR-17-0498. Epub 2018 May 21.
10
International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study.共识免疫评分用于结肠癌分类的国际验证:预后和准确性研究。
Lancet. 2018 May 26;391(10135):2128-2139. doi: 10.1016/S0140-6736(18)30789-X. Epub 2018 May 10.